#377 — The Future of Psychedelic Medicine 2

Episode Summary

Executive Summary: The episode examines the current state of psychedelic medicine, centered on MDMA-assisted therapy for PTSD and the FDA’s upcoming decision. Jenny Mitchell and Sarah Betty argue the data are promising but that research, regulation, training, and funding must evolve to handle the therapy’s powerful effects, risks, and need for integration.

Main Topics: MDMA-assisted therapy for PTSD (Priority: 5/5): The conversation focuses on Lycos/MAPS phase 3 trials of MDMA-assisted psychotherapy for PTSD, which showed striking symptom reductions and prompted intense interest, but also scrutiny from the FDA advisory committee. FDA scrutiny, blinding, and trial design (Priority: 5/5): The speakers discuss why psychedelic trials are hard to blind, why the study used remote telemedicine assessment, and how critics focused on placebo effects, bias, and adverse-event reporting. Therapy as part of the treatment model (Priority: 5/5): They argue psychedelic medicine is not just pharmacology; therapeutic setting, preparation, integration, and post-session support are likely essential to outcomes and must be standardized. Misconduct, ethics, and bringing the field above ground (Priority: 4/5): Allegations of therapist boundary violations are treated as serious but not field-defining; both guests say approval and regulation would improve accountability, reporting, and training. Systems thinking vs reductionist medicine (Priority: 4/5): Sarah Betty frames psychedelics as a challenge to mechanistic, pathology-based medicine, emphasizing psychoneuroimmunology, trauma, inflammation, and the whole-person model of care. Funding, access, and policy reform (Priority: 5/5): A major theme is the lack of public funding and the need for policy tools, state/federal support, expanded access, and right-to-try frameworks, especially for veterans and people in crisis. Non-psychedelic psychedelics and mechanisms of change (Priority: 3/5): The discussion explores whether the psychedelic subjective experience itself is necessary, or whether neuroplasticity alone could produce benefits via so-called psychoplastogens.

Key Arguments: MDMA shows unusually strong promise for PTSD, with roughly 70% of participants losing the PTSD diagnosis across phase 3 studies. The FDA advisory committee’s skepticism is not the same as an FDA rejection; the approval path may still exist through additional safeguards like a REMS plan. Unblinding is a real challenge in psychedelic trials, but it is not unique to psychedelics and was partly addressed through remote, blinded outcome assessment. Therapy is inseparable from the medicine in psychedelic treatment; integration and safe support likely affect durability and real-world outcomes. Reported therapist misconduct is serious but should motivate regulation, credentialing, and accountability rather than derailing the entire field. The existing mental-health system fails too many patients, creating demand for new treatments that address chronic, treatment-resistant conditions. A systems-based model better captures trauma, inflammation, family context, and social determinants than a purely reductionist drug model. There is a need to fund research and build infrastructure so the field can mature without relying on philanthropy or underground practice. Right-to-try and expanded-access pathways may be especially justified for veterans and terminally ill patients who have exhausted existing options.

Data Points: PTSD diagnosis loss in phase 3 studies: ~70% - Jenny Mitchell described the proportion of participants who lost their PTSD diagnosis across the two MDMA phase 3 studies. Veteran suicides: Almost 1 veteran per hour - Mitchell used this figure to underscore the severity of unmet need in PTSD treatment among veterans. Mental health burden worldwide: Nearly 1 billion people - Sarah Betty cited WHO-scale prevalence to argue for broader therapeutic innovation. Mental health burden in the U.S.: 1 in 5 Americans - Betty referenced this estimate to highlight how common mental illness is. U.S. mental health population: About 50 million people - Betty translated the 1-in-5 statistic into an approximate count. PTSD in the U.S.: About 13 million people - Betty cited this number while discussing the scale of PTSD. TREAT California proposed funding: $5 billion - Betty described the ballot initiative as a citizen-driven proposal to create a large psychedelic research funding agency. Study design timeline: About 13 years - Mitchell said it took roughly 13 years to finalize the phase 3 study design with the sponsor and FDA. Therapy/session duration: About 5-8 hours - The speakers repeatedly referenced long supervised psychedelic sessions and the need for integration afterward. FDA decision timing: Next month / mid-August - The discussion centered on the imminent FDA ruling on MDMA-assisted therapy.

Pivotal Quotes: "A therapist having sex with a patient is unethical. Full stop." — Sarah Betty: Betty argued that misconduct should be confronted directly and prevented through stronger regulation and training. "We don't have any great pharmacological therapeutics for PTSD." — Jennifer Mitchell: Mitchell summarized why MDMA-generated excitement has been so strong: current PTSD treatments often fail. "The perfect can become the enemy of the good here." — Sam Harris: Harris raised concern that emphasizing risks and complexity could block access to a potentially life-saving treatment.

Implications: If MDMA-assisted therapy is approved, the field will need formal training, oversight, integration support, and equitable access. The decision could shape psychedelic regulation, veteran care, and whether these therapies move from underground practice into accountable medicine.